Literature DB >> 23937608

EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma.

Wei Zhang1, Elizabeth B McQuitty, Randall Olsen, Hongxin Fan, Heather Hendrickson, Fermin O Tio, Keith Newton, Philip T Cagle, Jaishree Jagirdar.   

Abstract

CONTEXT: Lung cancer is the leading cause of cancer deaths worldwide. First-generation tyrosine kinase inhibitors improve progression-free survival in lung cancers with epidermal growth factor receptor (EGFR) mutations. EGFR mutations occur predominantly in exons 19 and 21 in lung adenocarcinomas of Asians (∼30%), whites (∼15%), and African Americans (∼19%). However, minimal information exists on the prevalence or type of genetic changes that occur in lung cancers in US Hispanic patients. We investigated the EGFR mutation frequency in primary lung adenocarcinomas in US Hispanics compared with non-Hispanic whites.
OBJECTIVE: To evaluate EGFR mutations in lung adenocarcinomas from US Hispanic patients compared with those from non-Hispanic white patients.
DESIGN: DNA samples were extracted from paraffin-embedded tissue of consecutive lung adenocarcinomas from 83 patients. Samples were collected from 40 Hispanics and 43 non-Hispanic whites. Mutations in EGFR were analyzed using a custom assay. Results.-Fourteen of 83 patients (16.9%) had EGFR mutations in their tumor DNA, including 6 of 40 Hispanics (15.0%) and 8 of 43 non-Hispanic whites (18.6%). No association with age, sex, or tumor stage was identified. Smoking history could not be obtained for most of the 83 patients, although 8 of the 11 patients with EGFR mutations for whom smoking history was obtained were nonsmokers. Most of the tumors with EGFR mutations (12 of 14; 85.7%) were acinar with lepidic or papillary subtypes. EGFR mutations occurred in exon 19 (42.8%), exon 18 (28.6%), exon 20 (28.6%), and exon 21 (14.3%). Two cases had 2 mutations identified in different exons.
CONCLUSION: The frequency of EGFR mutations is similar in US Hispanics compared with non-Hispanic whites.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23937608     DOI: 10.5858/arpa.2013-0311-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

Review 1.  Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?

Authors:  Berna C Özdemir; Gian-Paolo Dotto
Journal:  Trends Cancer       Date:  2017-03-06

Review 2.  Lung cancer mutations and use of targeted agents in Hispanics.

Authors:  W Douglas Cress; Alberto Chiappori; Pedro Santiago; Teresita Muñoz-Antonia
Journal:  Rev Recent Clin Trials       Date:  2014

3.  Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.

Authors:  Lorraine Pelosof; Chul Ahn; Ang Gao; Leora Horn; Alejandra Madrigales; Joan Cox; Dauphne McGavic; John D Minna; Adi F Gazdar; Joan Schiller
Journal:  J Natl Cancer Inst       Date:  2017-01-28       Impact factor: 13.506

4.  Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.

Authors:  Conor E Steuer; Madhusmita Behera; Lynne Berry; Sungjin Kim; Michael Rossi; Gabriel Sica; Taofeek K Owonikoko; Bruce E Johnson; Mark G Kris; Paul A Bunn; Fadlo R Khuri; Edward B Garon; Suresh S Ramalingam
Journal:  Cancer       Date:  2015-12-22       Impact factor: 6.860

5.  Hispanics/Latinos in the Bronx Have Improved Survival in Non-Small Cell Lung Cancer Compared with Non-Hispanic Whites.

Authors:  Madelyn Klugman; Xiaonan Xue; Mindy Ginsberg; Haiying Cheng; Thomas Rohan; H Dean Hosgood
Journal:  J Racial Ethn Health Disparities       Date:  2019-11-11

6.  EGFR Mutations in Latinos From the United States and Latin America.

Authors:  Ariel Lopez-Chavez; Anish Thomas; Moses O Evbuomwan; Liqiang Xi; Guinevere Chun; Tatiana Vidaurre; Oscar Arrieta; George Oblitas; Ana Belen Oton; Alejandro R Calvo; Arun Rajan; Mark Raffeld; Seth M Steinberg; Lorena Arze-Aimaretti; Giuseppe Giaccone
Journal:  J Glob Oncol       Date:  2016-03-09

7.  Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico.

Authors:  Ruifang Zheng; Zhiwei Yin; Albert Alhatem; Derek Lyle; Bei You; Andrew S Jiang; Dongfang Liu; Zsolt Jobbagy; Qing Wang; Seena Aisner; Jie-Gen Jiang
Journal:  Cancers (Basel)       Date:  2020-11-24       Impact factor: 6.639

Review 8.  Racial disparity in metabolic regulation of cancer.

Authors:  Kuldeep S Attri; Divya Murthy; Pankaj K Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-03-01

9.  Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.

Authors:  Lindsey Enewold; Anish Thomas
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.